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The  structural  characterization  and the anticoagulant  potential  of a  novel  heparin/heparan  sulfate-like
compound  from  the  heads  of Litopenaeus  vannamei  shrimp  are  described.  While  it is  distinct  from  either
heparin  or  heparan  sulfate,  enzymatic  depolymerization  and  nuclear  magnetic  resonance  spectroscopy
analyses  revealed  that this  molecule  does  share  some  structural  features  with  heparin,  such  as  the  high
degree  of N- and  6-O-sulfation  and  minor  N-acetylation,  and  with  heparan  sulfate,  in the glucuronic  acid
content.  Its  ability  to  stabilize  human  antithrombin  explains  its  signiﬁcant  anticoagulant  activity  in  aPTTeywords:
eparin
eparan sulfate
emorrhagic activity
ntithrombin
and  Factor-Xa  inhibition  assays.  Interestingly,  in contrast  to mammalian  heparin,  the  shrimp  compound
displayed  negligible  hemorrhagic  effect.  Together,  these  ﬁndings  have  particular  interest  since  they  reveal
a novel  molecule  with  signiﬁcant  anti-Xa  activity coupled  with  low  bleeding  effects  which  make  the
shrimp  heparin/HS-like  compound  a potential  alternative  for mammalian  heparin.nticoagulant
hermostabilization
. Introduction
Heparin and heparan sulfate (HS) are the most extensively stud-
ed glycosaminoglycans (Guerrini et al., 2013) and their structures
re qualitatively similar (Casu, Naggi, & Torri, 2010) in that both
olysaccharide chains are composed of 1 → 4 linked disaccharide
nits, consisting of -d-glucuronic acid (G) or -l-iduronic acid
I) and -d-glucosamine (A). Variable modiﬁcation patterns occur
t several positions of the constituent subunit disaccharides. The
 and, more rarely, G residues can be O-sulfated at position C-2
I2S and G2S, respectively) whereas A residues can be N-sulfated
ANS), N-acetylated (ANAC) and frequently 6-O-sulfated (A6S) (Bisio
t al., 2009; Guerrini et al., 2013; Rabenstein, 2002). Small numbers
f N,6-O-sulfated glucosamine (ANS,6S) residues can also possess
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an additional O-sulfate group at position C-3 (ANS,6S,3S). This rare
trisulfated glucosamine is a marker for the pentasaccharide motif
active for antithrombin (AT), resulting in inhibition of the major
coagulation cascade proteases, including Factor Xa (Guerrini et al.,
2013).
Both polymers are biosynthesized as proteoglycans through
alternate additions of G and ANAc residues to the tetrasac-
charide linkage region (-GlcA-(1,3)--Gal-(1,3)--Gal-(1,4)--
Xyl-1 → O-Ser). Next, a series of sequential N-deacetylation/N-
sulfation of ANAc residues, epimerization of some G to I and multiple
O-sulfations at different positions take place to modify the polysac-
charides (Rabenstein, 2002). Although biosynthesis of heparin and
HS chains occurs by the same reactions, the modiﬁcation degree
is different. Heparin undergoes more extensive uronic acid epi-
merization and sulfation, such that it has a higher iduronic to
glucuronic acid ratio and total O-sulfate group content (Casu &
Lindahl, 2001; Casu et al., 2010; Lyon & Gallagher, 1998; Molist
et al., 1998). In addition, the non-sulfated sequence G-ANAC is pre-
dominant in HS, whereas the trisulfated disaccharide (I2S-ANS,6S) is
the major repeating structural unit present in heparin (Bisio et al.,
2009; Guerrini et al., 2013).
Heparin has been used clinically as the drug of choice in the pre-
vention and treatment of thromboembolic diseases (Alban, 2008).
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owever, its use is accompanied by some side effects, frequently
equiring monitoring of partially activated thromboplastin time
nd resulting in other hemorrhagic complications (Nader et al.,
001). In addition, several adverse clinical manifestations and
eaths resulting from the use of contaminated heparins have been
eported (Blossom et al., 2008; Kishimoto et al., 2008; Rudd et al.,
011). These concerns have stimulated the search for alternative
nticoagulants with reduced side effects. Interestingly, compounds
tructurally related to heparin/HS with variable biological activi-
ies have been described in many species of invertebrates (Andrade
t al., 2013; Cassaro & Dietrich, 1977; Dietrich et al., 1985; Medeiros
t al., 2000; Santos et al., 2007). Previous studies have shown the
ccurrence of a non-hemorrhagic heparin analog in the heads of
he Litopenaeus vannamei shrimp, which has anti-inﬂammatory and
nti-angiogenic properties, but is devoid of anticoagulant activity
Brito et al., 2008; Dreyfuss et al., 2010).
Now, we describe the structural features, anticoagulant and
nti-hemostatic activities, in addition to the AT stabilization prop-
rties of a second distinct heparin/HS from L. vannamei,  which
epresents the most commonly farmed shrimp species in Brazil and
ne of the most commonly farmed in the world (Cahú et al., 2012).
. Experimental
.1. Materials
Heparan sulfate from bovine pancreas was a gift from the late
r. P. Bianchini (Opocrin Research Laboratories, Modena, Italy).
eparitinases I and II, and heparinase (heparinase I, EC4.2.2.7)
ere prepared as previously described (Dietrich et al., 1989).
odium heparin from porcine mucosa was obtained from Lab-
ratory Derivati Organici (Trino Vercellese, Italy). Chondroitin
-sulfate (CS-4) and chondroitin 6-sulfate (CS-6), extracted from
hale cartilage, and dermatan sulfate (DS) extracted from pig skin,
ere acquired from Miles Laboratories (Elhart, IN, USA).
.2. Isolation and puriﬁcation of heparin/heparan sulfate (H/HS)
rom shrimp heads
The isolation of hybrid H/HS from L. vannamei heads was  per-
ormed as described (Brito et al., 2008). Brieﬂy, 16 kg of shrimp
eads were defatted with acetone and submitted to proteolysis
t 60 ◦C for 24 h. Then, the polysaccharides extracted were com-
lexed with ion-exchange resin and eluted with 3.0 M NaCl. The
ool of glycosaminoglycans (GAGs) obtained was submitted to ace-
one fractionation to obtain F-0.5, F-0.7 and F-1.0 fractions. The
hrimp H/HS was then puriﬁed by ion-exchange chromatogra-
hy followed by NaCl elution (0.5, 0.8 and 1.0 M).  Efﬂuents were
nalyzed by carbazole assay to detect the presence of GAGs as pre-
iously described (Dische, 1947). The compounds eluted with 0.8 M
aCl were desalted by gel ﬁltration through a Sephadex G-25 col-
mn  by eluting with 10% ethanol. After lyophilization, the puriﬁed
hrimp H/HS compound (52.8 mg)  was analyzed.
.3. Electrophoresis
The shrimp H/HS was analyzed by agarose gel electrophoresis
sing two different buffers systems: 0.05 M 1,3-diaminopropane
cetate (PDA/Aldrich), pH 9.0, and the discontinuous system bar-
um acetate/PDA. Brieﬂy, aliquots (5 L) were applied to a 0.5%
garose gel (Bio-Rad) and run for 1 h at 100 V. The GAGs in
he gel were ﬁxed with 0.1% N-acetyl-N,N,N-trimethylammonium
romide solution. After 2 h, the gel was dried and stained with
.1% toluidine blue in acetic acid/ethanol/water (0.1:5:5, v/v/v) as
escribed by Dietrich and Dietrich (1976). Subsequently the gellymers 99 (2014) 372– 378 373
was destained with a solution containing acetic acid/ethanol/water
(0.1:5:5, v/v/v).
2.4. Enzymatic digestion
Enzymatic digestion was  performed as previously described
(Lima, Hughes, et al., 2013). Brieﬂy, 100 g of the isolated com-
pound and heparin were incubated with a mixture of heparin
lyases (2.5 mIU  each) and the disaccharides produced resolved on a
150 × 4.6 mm Phenosphere SAX column (Phenomenex, Torrance,
CA, USA) using a NaCl gradient of 0–1 M during 30 min  with a
1 mL/min ﬂux and UV detection at 232 nm.
2.5. Molecular weight determination
Samples were analyzed by GPC-HPLC on a 300 × 7.8 mm BioSep
SECTM S-2000 LC Column (Phenomenex, Torrance, CA, USA) using
isocratic elution (0.3 M Na2SO4 mobile phase) at a ﬂow rate of
1 mL/min and UV detection at 205 nm.  The column was  previously
calibrated with polysaccharides of known molecular weights (1.7,
4, 10, 16 and 20 kDa).
2.6. Nuclear magnetic resonance analysis
For NMR  experiments, the samples were deuterium exchanged
by repeated dissolution in D2O and freeze-drying. Spectra were
obtained from solutions in D2O at 25 ◦C, using TSP as standard
(ı = 0). All spectra were obtained with a Bruker 400 MHz, 600 MHz
AVANCE II or III NMR  spectrometer (Bruker GmbH, Silberstrei-fen,
Germany) with a triple resonance 5-mm probe and in Agi-
lent 600 MHz  System with 5-mm Cold Probe. 1D and 2D signal
assignments were performed using 1H-(zg, and zgpr) and HSQC
(hsqcetgpsi) programs. HSQC was acquired using 8–16 scans,
respectively, per series of 2 K × 512 W data points with zero ﬁll-
ing in F1 (4 K) prior to Fourier transformation (Lima, Viskov, et al.,
2013).
2.7. Puriﬁcation of antithrombin (AT)
AT was puriﬁed from fresh citrated human plasma by afﬁn-
ity chromatography on heparin-sepharose. Brieﬂy, human plasma
was loaded onto a heparin-sepharose column, which had been
equilibrated with 0.1 M Tris–HCl, 0.01 M sodium citrate and 0.25 M
sodium chloride. Unbound and weakly bound proteins were eluted
from the column by washing with 0.1 M Tris–HCl, 0.01 M sodium
citrate and 0.25 M sodium chloride followed by 0.1 M Tris–HCl,
0.01 M sodium citrate and 0.5 M sodium chloride (5 column vol-
umes). AT was eluted with 0.1 M Tris–HCl, 0.01 M sodium citrate
and 2 M sodium chloride, dialyzed against 12.5 mM  phosphate
buffer and concentrated.
2.8. Differential scanning ﬂuorimetry (DSF)
AT was at 30 nM in the presence of an excess of GAG, based
where necessary on weight average molecular weight (Mw). The
dye Sypro OrangeTM was  employed at 100× concentration (5 L
of 5000× concentration dye into 245 L fresh deionized water).
The dye has an excitation wavelength of 300 or 470 nm, and emits
at 570 nm when bound to hydrophobic residues. The protein was
subjected to a step-wise temperature gradient, from 32 ◦C to 85 ◦C
in 0.5 ◦C steps. There was  an initial 2 min  incubation period at
31 ◦C and 5 s between each temperature increase to equilibrate.
Data were collected for 30 s at each temperature (Uniewicz et al.,
2010). First derivatives of the melting curves were employed with
Solvitzky–Golay smoothing with a second order polynomial.
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Fig. 1. (A) Puriﬁcation of the fraction F-0.7 by ion-exchange chromatography on DEAE Sephacel. The column was eluted with a salt gradient represented in the graph by
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.9. Anticoagulant activity
The activated partial thromboplastin time (aPTT) assay was
erformed according to the method of the kit APTTest (Rosario,
rgentina). Heparin, heparan sulfate and shrimp H/HS were dis-
olved in physiological saline to the appropriate concentrations
generating a volume of 10 L) and incubated with 90 L of plasma
t 37 ◦C during 3 min. Then, 100 L of bovine cephalin was added
nd incubated at 37 ◦C. After 3 min  of incubation, 100 L of pre-
armed 0.25 M CaCl2 solution were added to the mixture and the
lotting time was  measured in triplicate using Quick Timer Coagu-
ometer (Drake Electronica Commerce Ltd., Sao Paulo, Brazil).
.10. Assay for the anti-Xa activity
The anti-Xa activity assay was conducted in a 96-well
icroplate according to the instructions of Biophen Heparin Anti-
a kit (HYPHEN Biomed, ref: 221010) as follows: 40 L of AT was
ncubated at 37 ◦C for 2 min  in the presence of increasing concen-
rations of heparin or shrimp H/HS diluted in buffer pH 8.4 (0.05 M
ris, 0.175 M NaCl, 0.0075 M EDTA, containing 0.1% polyethylene
lycol). 40 L of puriﬁed bovine Factor Xa (FXa) was then added
o each well, mixed and incubated at 37 ◦C for exactly 2 min. Then,
0 L of a chromogenic substrate for FXa was added and the mix-
ure was incubated for 2 min  at 37 ◦C. Following incubation, 80 L of
0% acetic acid was added to stop the reaction and the absorbance
as measured against a corresponding blank.
.11. Residual hemorrhagic effect
The residual hemorrhagic effect of shrimp H/HS compound was
nalyzed by a modiﬁed model of topical scariﬁcation in rat tail (Cruz
 Dietrich, 1967). After anesthesia with ketamine and xylazine in
 1:1 (v/v) proportion, a scar was made with a surgical blade in the
istal portion of the tail. Then, the tail was then dipped vertically in
hysiological saline solution, dabbed with gauze and dipped again
n fresh saline to observe bleeding. The tail was dipped in a solu-
ion containing shrimp H/HS or heparin at different concentrationsnd (2) shrimp H/HS obtained by ion-exchange and gel chromatography of F-0.7 on
atan sulfate (DS) and heparan sulfate (HS). F- heparin fast moving component; S-
for 2 min  and then washed extensively with saline solution. The
treated tail was immersed in new physiological saline solutions for
40 min  and the amount of blood was  measured by Bradford assay.
The results were expressed as the sum of the protein values of each
tube minus the amount of protein present before the exposure to
the test substance.
3. Results and discussion
3.1. Isolation and puriﬁcation of shrimp H/HS
The compounds isolated from shrimp heads following proteo-
lysis and fractionation by ion-exchange resin were precipitated
with acetone in different proportions to obtain fractions named
F-0.5, F-0.7 and F-1.0. The electrophoretic proﬁles of such fractions
in diaminopropane/acetate buffer (PDA) indicated the presence
of compounds with migration between heparan and dermatan
sulfate, although the F-0.7 and F-1.0 fractions also possess a
band corresponding to chondroitin sulfate (data not shown). The
analysis of the 13C NMR  spectrum shows the presence of low
intensity signals (∼63 ppm e ∼54 ppm) (data not shown) corre-
sponding to N-acetylated galactosamine residues, which conﬁrms
the presence of galactosaminoglycans. The shrimp H/HS was
further puriﬁed from fraction F-0.7 by anion-exchange chromatog-
raphy on DEAE–Sephacel using a step-wise salt gradient (Fig. 1A).
The fraction eluted with 0.8 M NaCl yielded 70.0% of total uronic
acid content and was further desalted by gel chromatography on
Sephadex G-25. In the discontinuous barium/PDA buffer, in which
mammalian heparin is fractionated in three bands named fast,
intermediate and slow moving components (Bianchini et al., 1980;
Medeiros et al., 2000), the shrimp H/HS compound showed only one
band, which migrates as heparan sulfate and/or as the fast mam-
malian heparin component (Fig. 1B). Such electrophoretic behavior
could indicate that the compound isolated from shrimp has a high
disulfated disaccharide content (Volpi, 1993). Similar behavior was
also observed in heparin-like compounds from other crustacean
species, such as Penaeus brasiliensis shrimp (Dietrich et al., 1999)
and Artemia franciscana brine shrimp (Chavante et al., 2000).
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etrasaccharide.
.2. Enzymatic depolimerization
The disaccharide composition of the shrimp H/HS was
etermined by enzymatic depolymerization with a mixture of hep-
rinase and heparitinases I and II from Flavobacterium heparinum.
pon the combined action of these enzymes, shrimp H/HS yielded
 high content of disulfated disaccharide (U-ANS,6S/U,2S-ANS)
Fig. 2B), contrasting with porcine mucosal heparin, in which the
risulfated disaccharides are predominant (Fig. 2A). Since disulfated
isaccharides are mainly formed by hepritinase II action, these
esults suggest that shrimp H/HS is more extensively degraded by
his enzyme, similar to heparin-like polysaccharides from other
nvertebrate species (Andrade et al., 2013; Dietrich et al., 1985,
989, 1999; Medeiros et al., 2000). In contrast to heparan sulfates,
n which around 50–60% of all disaccharides are U-ANAc/U-
NS (Andrade et al., 2013; Dietrich et al., 1998; Zhang, Xie, Liu, Liu,
 Linhardt, 2009), the results show that the molecule puriﬁed from
hrimp contains just 10.7% of these units. In fact, the high degree
f N,6-O-sulfation and minor N-acetylation are the main structural
eatures of shrimp H/HS observed by enzymatic depolymerization.
ogether, the data suggest the occurrence of an atypical molecule
ith characteristics of a hybrid heparin and heparan sulfate.
.3. Molecular weight and structural features of shrimp
eparin/heparan sulfate
Shrimp H/HS showed an average molecular weight of 15 kDa,
imilar to porcine heparin (∼16 kDa) and lower than bovine hep-
ran sulfate (∼25 kDa). The compound was characterized by 1H/13C
eteronuclear single-quantum coherence (HSQC)-NMR analysis,
s shown in Fig. 3A and B and Table 2. Following H/C signal
orrelation, the compound isolated from shrimp heads exhibited
imilar characteristics to signals ascribed to porcine heparin. An
nteresting observation is the absence of signals corresponding to
on-sulfated iduronic acid in the shrimp H/HS spectra. This result
uggests a particular mode of shrimp H/HS synthesis which, after
he epimerization step, results in all iduronic acid residues being
-O-sulfated, contrasting with the biosynthesis process that occurs
n mammalian heparin and HS. In addition, combined analysis of H/HS (B) following the combined action of heparinase and heparitinases I and
 UA(2S)-ANS; (7) UA(2S)-ANAc,6S; (8) UA(2S)-ANS(6S); * residual undigested
the data from the enzymatic depolymerization and HSQC spectra
show that the shrimp H/HS polymer consists mainly of disaccharide
units containing N,6-sulfated glucosamine linked to glucuronic acid
(G-ANS,6S), N-sulfated glucosamine linked to 2-sulfated iduronic
acid (I2S-ANS) and N,6-sulfated glucosamine linked to 2-sulfated
iduronic acid (I2S-ANS,6S). The monosaccharide content of shrimp
H/HS is shown in Table 1. A relatively high content of ANS (72.5%)
and 6-O-sulfation (71.5%) together with low degree of ANAc (22.5%)
report a structure which is very close to mammalian heparin and
distinct from heparan sulfate (Casu & Lindahl, 2001; Casu et al.,
2010; Lyon & Gallagher, 1998). On the other hand, in HSQC anal-
ysis from shrimp H/HS, the signals attributed to G are higher than
I2S residues, resembling the higher ratio of glucuronic/iduronic
acid, similar to heparan sulfate. These differences have also been
observed in mollusk and crustacean heparin-like compounds,
which also contain high proportions of G residues (Andrade et al.,
2013; Dietrich et al., 1985, 1989, 1999; Medeiros et al., 2000). Taken
together, the NMR  and enzymatic depolymerization data conﬁrm
that the molecule isolated from shrimp shares structural features
with both heparin and heparan sulfate, consequently, it is most
appropriate to deﬁne it as a hybrid of heparin and heparan sul-
fate. Other interesting data include the presence of about 5% of
the rare 3-O-sulfation on N-sulfated glucosamine residues. Such
residues are usually undetectable in HS (Guerrini, Guglieri, Naggi,
Sasisekharan, & Torri, 2007; Guerrini, Naggi, Guglieri, Santarsiero, &
Torri, 2005). However, A3S is found in the high afﬁnity AT-binding
site of heparin (Linhardt, Wang, Loganathan, & Bae, 1992) and is
strongly associated with the anti-FXa activity of heparin (Guerrini
et al., 2007). For this reason, it became of great interest to evaluate
the anticoagulant potential of the hybrid shrimp H/HS.
3.4. Anticoagulant activity assays
The anticoagulant activity of the shrimp H/HS compound was
investigated by the classical clotting assay aPTT and by determining
its capacity to catalyze antithrombin mediated inactivation of fac-
tor Xa using porcine heparin (190 IU/mg) as a reference. As shown
in Fig. 4, at 5 g/mL, porcine heparin prolonged the clotting time
for more than 240 s, detected by aPTT. The same effect is achieved
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Fig. 3. 1H/13C heteronuclear single-quantum coherence (HSQC)-NMR spectrum. (A) Major identiﬁed signal used for and (B) Anomeric region. N,6-sulfated glucosamine
linked  to glucuronic acid (G-ANS,6S); N-sulfated glucosamine linked to 2-sulfated iduronic acid (I2S-ANS); N,6-sulfated glucosamine linked to 2-sulfated iduronic acid (I2S-
ANS,6S). Signals used for composition analysis are ANAc (2.04/25 ppm), ANS (3.46/60.7 ppm), A3S (3.45/60 ppm), A6OH (3.86/62.3), A6S (4.38/69.1 ppm), G (3.38/75.8 ppm), I2S
(5.20/102.1).
Table 1
Saccharide composition calculated by 2D HSQC spectrum integration (A) and (B) HPLC disaccharide analysis. Glucosamine N-sulfate (ANS); Glucosamine N-acetyl (ANAc);
Glucosamine 3-O-sulfate (A3S); Glucosamine 6-O-sulfate (A6S); Glucuronic acid (G); Iduronic acid (I); Iduronic acid 2-O-sulfate (I2S).
(A) Monosaccharide (%)
ANS ANS ANAc A3S A6S G I I2S
72.5 22.5 5.1 71.5 77.6 n.d. 22.4
(B)  Disaccharides (%)
UA-
ANAc/D0A0
UA-
ANS/D0S0
UA-
ANAc(6S)/D0A6
UA(2S)-
ANAc/D2A0
UA-
ANS(6S)/D0S6
UA(2S)-
ANS/D2S0
UA(2S)-
ANAc(6S)/D2A6
UA(2S)-
ANS(6S)/D2S6
Shrimp H/HS 11.02 9.14 4.51 3.15 28.87 17.63 0.00 25.68
3.89 
5.24 
2.20 
b
t
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t
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tein stability have been achieved by unfractionated heparin (UFH)
and AT-binding pentasaccharide (59.25 and 65.25 ◦C, respectively),
the shrimp polysaccharide also showed a considerable increase in
the thermal stability of AT (57.25 ◦C). The data showed that thePancreas HS 45.77 17.03 11.08 
Lung  HS 28.69 16.87 17.99 
Heparin (6th Int. Std.) 3.42 2.75 3.71 
y the shrimp compound at a higher concentration, demonstrating
hat it is able to inhibit the clot formation via the intrinsic pathway.
ext, we examined whether the molecule from shrimp was able
o inhibit directly the activity of FXa. As shown in Fig. 5, despite
ts lower activity, it inhibited the FXa activity in a concentration-
ependent manner, reaching approximately 97% of inhibition at
bout 0.6 g/mL. The anticoagulant action of heparin and heparin-
ike saccharides depends their ability to bind to and potentiate the
nhibitory activity of AT against plasma proteases. More recently, it
as been shown that this activity is strongly correlated with ther-
al  stabilization of AT (Lima, Hughes, et al., 2013), which led us to
nvestigate the effect of the compound on AT stability..5. Thermostabilizing effect of shrimp H/HS compound on AT
The thermostabilizing effect of shrimp H/HS saccharide on AT
as evaluated by differential scanning ﬂuorimetry (DSF) and the
able 2
H/13C major chemical shifts for the shrimp H/HS.
ANAc G ANS,6X I2S ANX,6X3S
1 5.31/100 4.6/104 5.4–5.31/100 5.20/102.1 5.53/98.8
2  – 3.38/75.8 3.46/60.7 4.33/78.6 3.45/60
3  – – – –
4 – – – –
5 – – – –
6 – – 3.86–4.38/62.3–69.1 –
CH3 2.04/25 – – –7.19 8.79 0 6.23
10.65 12.66 0 7.90
9.25 8.10 1.51 69.06
results are shown in Fig. 6. Although the strongest effects on pro-Fig. 4. Anticoagulant activity of heparin and shrimp H/HS by aPTT (activated partial
thromboplastin time) assay. (•) Heparin; () Shrimp H/HS.
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Fig. 7. Bleeding activity of the shrimp H/HS glycosaminoglycan and porcine intesti-ig. 5. Anti-Xa activity of mammalian heparin and shrimp H/HS. (•) Heparin; ()
hrimp H/HS.
nticoagulant activity of the compound from shrimp results, at least
n part, from its ability to bind and stabilize AT. Curiously, crus-
aceans do not possess blood coagulation cascade similar to that
f mammals; a fact that makes the occurrence of molecules that
ct upon coagulation proteins remarkable and suggests that the
hrimp H/HS molecules can modulate the activity of endogenous
erine proteases.
.6. Bleeding time
Owing to its ability to interfere in the hemostatic balance,
he clinical use of mammalian heparin is involved with some
ndesirable effects, such as hemorrhage, therefore, the residual
emorrhagic effect of shrimp H/HS was investigated. As shown in
ig. 7, at 100 g/mL, porcine heparin has a potent hemorrhagic
ffect. Interestingly, the molecule isolated from shrimp, despite
ts anticoagulant potential, had an insigniﬁcant effect on bleeding.
hese results are in agreement with previous ﬁndings that there is
ig. 6. Thermostabilizing effect of Shrimp H/HS on AT evaluated by differential scan-
ing ﬂuorimetry (DSF). () AT; (•) AT:Pentasaccharide; () AT:UFH; () AT:Shrimp
/HS.nal mucosa heparin (100 g/mL) or shrimp H/HS (100 g/mL) applied topically, and
the  bleeding potency measured after 2 min following saline solution washing. (•)
mammalian heparin, () shrimp H/HS.
no correlation between hemorrhagic activity and anti-Xa activity
or inhibition of clot formation (Boucas et al., 2012; Nader, Tersariol,
& Dietrich, 1989). In fact, it was  earlier proposed that the antihe-
mostatic activity of heparin is due to its binding to myosin ATPase
molecules of the injured vessels and consequent inhibition of the
normal muscular contractility (Cruz & Dietrich, 1967). Thus, it could
be speculated that the shrimp H/HS compound is not able to bind to
myosin ATP molecules with the same afﬁnity of heparin, so that it
must be dislodged after washes with saline solutions, as described
in Section 2.
4. Conclusions
The results describe a novel glycosaminoglycan isolated from
heads of shrimp L. vannamei which possesses a high degree of
N,6-sulfation and minor N-acetylation together with the high con-
tent of glucuronic acid and an absence of non-sulfated iduronic
acid. Despite exhibiting lower anticoagulant activity than heparin,
its lower hemorrhagic effect and the fact that it is obtained from
shrimp farm waste makes this GAG a suitable candidate as an alter-
native for mammalian heparin.
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